Fig. 6: TNF-TRPM2 axis elicits the FPP-induced inflammatory response in BD-PMN.

A The expression levels of TRPM2 in HC-PMN were assayed by qRT-PCR, after incubation with a medium prepared from the serum of active BD and HC (N = 20). B ELISA of proinflammatory cytokines, including TNF, IL-6, and IFN-γ in the serum from HC and BD (N = 16). C The expression levels of TRPM2 in HC-PMN after incubation with medium prepared from 50 ng/mL TNF, IL-6, and IFN-γ (N = 7). D The mRNA expression levels of TRPM2 in HC-PMN incubated before and after TNF-neutralizing antibody addition to active BD serum (N = 20). E The mRNA expression levels of TRPM2 in PMN from BD patients before and after treatment with TNF inhibitors (N = 7). F–G The quantification of proinflammatory cytokines (N = 8, (F) and NETs-dsDNA (N = 8, G in FPP-stimulated BD-PMN after preincubation with BD serum in the presence or absence of TNF-neutralizing antibody. N for all experiments were biological replicates. Data are presented as mean ± SD; error bars indicate the SD. A two-sided p-value < 0.05 was considered statistically significant, with *p < 0.05, **p < 0.01, and ***p < 0.001, indicating significant differences. Independent t-tests were used in (A, D, and G). Paired t-tests were used in E. Source data are provided as a Source Data file. One-way ANOVA tests were used in (B and C) and two-way ANOVA tests were used in F, with the p-value adjusted for multiple comparisons by FDR using the two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli.